Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
PMP, Off-Patent Drug Rules to Be Major Topics for 2024 Reform: MHLW Pharma Management Director
The review of the price maintenance premium (PMP) for innovative medicines and rules related to off-patent long-listed products (LLPs) will be the focus of the next drug pricing reform scheduled for April 2024, Takashi Yasukawa, pharmaceutical management director at the…
To read the full story
Related Article
- FY2024 Reform Heralds Shift to Funding Cycle within Drug Budget: MHLW Pharma Director
December 28, 2023
- Japan’s Reform Timeline Sees Major Updates for Text on Drug Pricing Overhaul
December 23, 2022
- Japan to Cut 310 Billion Yen in Drug Spending in FY2023 Off-Year Revision: Ministers
December 22, 2022
- Special PMP Increase to Offset 95% of Price Cuts for 150 Products: FY2023 Revision
December 22, 2022
- Chuikyo Will Consider Any Proposals of New Panel on Drug Pricing: Pharma Management Director
August 3, 2022
REGULATORY
- Japan to Designate International Clinical Trial Hubs in FY2027
August 28, 2026
- MHLW Tax Reform Requests Cover Support for MCM Preparedness
August 28, 2026
- Patient Group Flags Risks of Inconsistent Decisions on OTC-Like Drug Charges
August 28, 2026
- MHLW Pharma Bureau Eyes 12 Billion Yen to Boost Plasma Product Production
August 28, 2026
- Novo, Lilly Want Reimbursement Support for Obesity Care: LDP Hearing
August 28, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…